Published in Iowa Orthop J on January 01, 2006
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci (2013) 2.03
RNAi and small interfering RNAs in human disease therapeutic applications. Trends Biotechnol (2010) 1.80
Exosomes as a tumor immune escape mechanism: possible therapeutic implications. J Transl Med (2008) 1.28
Endotoxin and cancer. Environ Health Perspect (2009) 1.17
Listeria and Salmonella bacterial vectors of tumor-associated antigens for cancer immunotherapy. Semin Immunol (2010) 1.09
Therapeutic cancer vaccines: past, present, and future. Adv Cancer Res (2013) 0.99
Cancer immunotherapy: are we there yet? Exp Hematol Oncol (2013) 0.98
Targeting tumors with salmonella Typhimurium- potential for therapy. Oncotarget (2010) 0.97
Immunotherapy in gastric cancer. World J Gastroenterol (2014) 0.96
Bacteria in Cancer Therapy: Renaissance of an Old Concept. Int J Microbiol (2016) 0.95
Potent and tumor specific: arming bacteria with therapeutic proteins. Ther Deliv (2015) 0.86
Myeloid-derived suppressor cells: a double-edged sword? Int J Exp Pathol (2011) 0.85
Necrosis, and then stress induced necrosis-like cell death, but not apoptosis, should be the preferred cell death mode for chemotherapy: clearance of a few misconceptions. Oncoscience (2014) 0.84
Survivin: a unique target for tumor therapy. Cancer Cell Int (2016) 0.84
Immunotherapy for solid tumors--a review for surgeons. J Surg Res (2013) 0.83
From humble beginnings to success in the clinic: Chimeric antigen receptor-modified T-cells and implications for immunotherapy. Exp Biol Med (Maywood) (2015) 0.82
Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors. J Immunol Res (2015) 0.82
Immunotherapy of Childhood Sarcomas. Front Oncol (2015) 0.81
Immunotherapeutic advancements for glioblastoma. Front Oncol (2015) 0.81
Targeted Therapy in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (LA-R/M HNSCC). Cancers (Basel) (2016) 0.81
Vaccine adjuvants as potential cancer immunotherapeutics. Int Immunol (2016) 0.80
Reevaluating the concept of treating experimental tumors with a mixed bacterial vaccine: Coley's Toxin. Clin Dev Immunol (2012) 0.80
Tumour-targeting bacteria-based cancer therapies for increased specificity and improved outcome. Microb Biotechnol (2017) 0.79
Current Immunotherapies for Sarcoma: Clinical Trials and Rationale. Sarcoma (2016) 0.79
The Utilization of the Immune System in Lung Cancer Treatment: Beyond Chemotherapy. Int J Mol Sci (2016) 0.79
Harnessing the Microbiome to Enhance Cancer Immunotherapy. J Immunol Res (2015) 0.79
The efficacy versus toxicity profile of combination virotherapy and TLR immunotherapy highlights the danger of administering TLR agonists to oncolytic virus-treated mice. Mol Ther (2012) 0.78
Opportunities and challenges in combination gene cancer therapy. Adv Drug Deliv Rev (2015) 0.78
Melanoma vaccines: mixed past, promising future. Surg Clin North Am (2014) 0.78
A Salmonella nanoparticle mimic overcomes multidrug resistance in tumours. Nat Commun (2016) 0.78
Brucella spp. Lumazine Synthase Induces a TLR4-Mediated Protective Response against B16 Melanoma in Mice. PLoS One (2015) 0.77
In Hyperthermia Increased ERK and WNT Signaling Suppress Colorectal Cancer Cell Growth. Cancers (Basel) (2016) 0.77
Chemical compounds from anthropogenic environment and immune evasion mechanisms: potential interactions. Carcinogenesis (2015) 0.77
Precambrian origins of the TNFR superfamily. Cell Death Discov (2016) 0.76
The biography of the immune system and the control of cancer: from St Peregrine to contemporary vaccination strategies. BMC Cancer (2014) 0.76
Synthetic biology: Bacteria synchronized for drug delivery. Nature (2016) 0.76
Bacterial immunotherapy of gastrointestinal tumors. Langenbecks Arch Surg (2011) 0.76
Cancer immunotherapy trials: leading a paradigm shift in drug development. J Immunother Cancer (2016) 0.76
Alarmins released during local antitumor treatments play an essential role in enhancing tumor growth inhibition at treated and non-treated sites via a derivative of CCL3. Oncoimmunology (2014) 0.75
Manipulation of Innate and Adaptive Immunity through Cancer Vaccines. J Immunol Res (2017) 0.75
Local Salmonella immunostimulation recruits vaccine-specific CD8 T cells and increases regression of bladder tumor. Oncoimmunology (2015) 0.75
Intralesional Immunotherapy for Metastatic Melanoma: The Oldest and Newest Treatment in Oncology. Crit Rev Oncog (2016) 0.75
Mechanistic and pharmacologic insights on immune checkpoint inhibitors. Pharmacol Res (2017) 0.75
Overcoming tumor immune evasion with an unique arbovirus. J Transl Med (2015) 0.75
The challenges of solid tumor for designer CAR-T therapies: a 25-year perspective. Cancer Gene Ther (2017) 0.75
Intratumoral delivery of mRNA: Overcoming obstacles for effective immunotherapy. Oncoimmunology (2015) 0.75
Antibody Therapeutics in Oncology. Immunotherapy (Los Angel) (2016) 0.75
Harnessing immunosurveillance: current developments and future directions in cancer immunotherapy. Immunotargets Ther (2014) 0.75
Oral Administration of Polymyxin B Modulates the Activity of Lipooligosaccharide E. coli B against Lung Metastases in Murine Tumor Models. PLoS One (2016) 0.75
Metastatic MTLn3 and non-metastatic MTC adenocarcinoma cells can be differentiated by Pseudomonas aeruginosa. Biol Open (2013) 0.75
Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment. Onco Targets Ther (2016) 0.75
A New Concept of Enhancing Immuno-Chemotherapeutic Effects Against B16F10 Tumor via Systemic Administration by Taking Advantages of the Limitation of EPR Effect. Theranostics (2016) 0.75
Molecular imaging of biological gene delivery vehicles for targeted cancer therapy: beyond viral vectors. Nucl Med Mol Imaging (2010) 0.75
A current perspective on cancer immune therapy: step-by-step approach to constructing the magic bullet. Clin Transl Med (2017) 0.75
Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. Oncologist (2016) 0.75
Targeted Cancer Therapy Using Engineered Salmonella typhimurium. Chonnam Med J (2016) 0.75
Salmonella-Mediated Cancer Therapy: Roles and Potential. Nucl Med Mol Imaging (2016) 0.75
Nano-based delivery of RNAi in cancer therapy. Mol Cancer (2017) 0.75
The interplay between metabolic remodeling and immune regulation in glioblastoma. Neuro Oncol (2017) 0.75
Bacterial outer membrane vesicles suppress tumor by interferon-γ-mediated antitumor response. Nat Commun (2017) 0.75
Turbocharging vaccines: emerging adjuvants for dendritic cell based therapeutic cancer vaccines. Curr Opin Immunol (2017) 0.75
The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. Clin Orthop Relat Res (1991) 3.79
Coley's toxins in perspective. Nature (1992) 3.40
Bone cancers. Cancer (1995) 3.17
II. Contribution to the Knowledge of Sarcoma. Ann Surg (1891) 2.21
Dr William Coley and tumour regression: a place in history or in the future. Postgrad Med J (2003) 1.72
Coley toxins--the first century. Adv Exp Med Biol (1990) 1.18
Fever and cancer in perspective. Cancer Immunol Immunother (2001) 1.14
Current status of adoptive immunotherapy of cancer. Crit Rev Oncol Hematol (1996) 1.02
Clinical effect of Coley's toxin. II. A seven-year study. Cancer Chemother Rep (1962) 0.92
The Registry of Bone Sarcoma. A history. Iowa Orthop J (1995) 0.87
Innovations and strategies for the development of anticancer vaccines. Expert Opin Pharmacother (2000) 0.86